NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()


IDEXX Laboratories Inc. Nasdaq Global Select
Open: $542.08 High: $543.284 Low: $495.58 Close: $500.86
Range: 2021-03-02 - 2021-03-03
Volume: 543,419
Market: Open
Powered by Finage Stock APIDelayed data
IDEXX Laboratories Inc. One IDEXX Drive Westbrook ME, 4092
IDEXX Laboratories Inc develops, manufactures and distributes products and provide services for companion animal veterinary, livestock and poultry, dairy and water testing markets.
  • CEO: Jonathan W. Ayers
  • Employees: 7,600
  • Sector: Healthcare
  • Industry: Medical Diagnostics & Research
Latest news about the IDXX
  • Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?

    Is (IDXX) Outperforming Other Medical Stocks This Year?

    View More →
  • Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

    Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

    View More →
  • Announcing: IDEXX Laboratories (NASDAQ:IDXX) Stock Soared An Exciting 581% In The Last Five Years

    Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...

    View More →
  • Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

    Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

    View More →
  • NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines

    NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

    View More →
  • Why This Under-the-Radar Growth Stock Will Be the Top Dog in 2021

    When it comes to pet healthcare, Idexx Laboratories (NASDAQ: IDXX) is arguably the best in show. As a leading veterinary diagnostics firm, Idexx provides instruments (testing equipment) and consumables (diagnostic tests) that veterinarians need to run their practices and easily perform diagnostic tests. Essentially, Idexx Labs offers an all-in-one suite of products that handle everything from workflow management to blood and chemistry analyzers, even offering outside reference labs for smaller practices that wish to get accurate and timely results in two days or less.

    View More →
  • Love Your Pets? Buy and Hold This Growth Stock for Life, Too

    If you have ever wanted to invest in a company that helps keep your furry friend healthy, look no further than Idexx Labs (NASDAQ: IDXX). Idexx offers everything veterinarians need to test your pet for all manners of ailments. The company provides the equipment used to run diagnostic tests as well as the testing kits that go with these devices.

    View More →
  • IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

    IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in two upcoming conferences:

    View More →
  • Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise

    Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.

    View More →
  • Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

    Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

    View More →
  • Medtronic's (MDT) Nellcor Favored in Study Over Masimo's Oximetry

    Latest study favors Medtronic's (MDT) Nellcor Pulse Oximetry for all newborns considered for study, unlike from those newborns with Masimo's oximeter.

    View More →
  • QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

    QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

    View More →
  • Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2

    Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.

    View More →
  • Align Technology (ALGN) Beats on Q4 Earnings, Margins Up

    Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.

    View More →
  • The Cooper Companies (COO) Unit Gets a Boost From New Buyout

    The Cooper Companies (COO) arm's buyout drives its growing portfolio of medical products, which revolves around clinic and practice-based women's healthcare

    View More →
  • IDEXX Laboratories Inc (IDXX) Q4 2020 Earnings Call Transcript

    IDXX earnings call for the period ending December 31, 2020.

    View More →
  • IDEXX (IDXX) Earnings Beat Estimates in Q4, Margins Rise

    IDEXX (IDXX) registeres strong contribution from its CAG business in the fourth quarter despite pandemic-induced challenges.

    View More →
  • Why You Should Add AngioDynamics (ANGO) to Your Portfolio

    Investor confidence is high in AngioDynamics (ANGO) stock, courtesy of its solid prospects.

    View More →
  • Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates

    Idexx (IDXX) delivered earnings and revenue surprises of 40.56% and 5.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    View More →
  • Recap: IDEXX Laboratories Q4 Earnings

    Shares of IDEXX Laboratories (NASDAQ:IDXX) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were up 69.23% year over year to $1.76, which beat the estimate of $1.40. Revenue of $720,938,000 rose by 19.08% from the same period last year, which beat the estimate of $681,020,000. Looking Ahead The upcoming fiscal year's EPS expected to be between $7.39 and $7.71. The upcoming fiscal year's revenue expected to be between $3,065,000,000 and $3,120,000,000. How To Listen To The Conference Call Date: Feb 02, 2021 View more earnings on IDXX Time: 08:30 AM ET Webcast URL: Price Action Company's 52-week high was at $516.87 Company's 52-week low was at $168.65 Price action over last quarter: Up 15.91% Company Overview Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. Idexx gets about 38% of its revenue from outside the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 2, 2021Earnings Preview for IDEXX Laboratories© 2021 Benzinga does not provide investment advice. All rights reserved.

    View More →